GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
In patients with chronic kidney disease, adding a GLP-1 receptor agonist was associated with fewer major adverse kidney events (HR 0.70) than SGLT2 inhibitors alone.
Diabetes, Obesity & Metabolism
In adult patients with chronic kidney disease, adding a glucagon-like peptide-1 receptor agonist (GLP-1RA) to sodium-glucose co-transporter-2 inhibitor (SGLT2i) therapy was associated with reduced kidney complications. Researchers analyzed records from the TriNetX Global Collaborative Network between June 2020 and December 2023. The total cohort included 112,596 individuals with CKD, of whom 16,460 received combination therapy and 96,136 received SGLT2i monotherapy. Through 1:1 propensity score matching, investigators followed 16,224 matched patient pairs over a median of 12 months. Compared to SGLT2i monotherapy, combination therapy was associated with a lower rate of major adverse kidney events (HR 0.70; 95% CI 0.65-0.74). The authors observed incremental reductions in kidney disease progression and cardiovascular events, indicating additive cardiorenal benefits particularly in patients with obesity.
Why it matters
Renal and cardiovascular function steadily deteriorate with age, representing major drivers of morbidity in older populations. Identifying additive benefits between existing metabolic therapies provides a potential strategy to slow organ aging and protect against multi-system decline.
Caveats
The findings rely on retrospective observational health records rather than a prospective intervention, and the median follow-up was limited to 12 months. Randomized controlled trials are needed to confirm the additive benefits of this drug combination.
The paper
Show 6 more authors
Habib R Khan, Saad Ahmed Waqas, Gerry P. McCann, Amit Garg, Mohammed Shurrab, Kamlesh Khunti,Dow University of Health Sciences · University of Leicester
Diabetes, Obesity & Metabolism · 27 Sep 2026